Kurs
-3,15%
Likviditet
2,75 MNOK
Kalender
| Tid* | ||
| 2025-02-13 | 07:30 | Bokslutskommuniké 2024 |
| 2025-01-09 | N/A | Extra Bolagsstämma 2025 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-25 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2024-04-24 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-21 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2023-04-20 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-21 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2022-04-20 | - | Årsstämma |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-22 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2021-04-21 | - | Årsstämma |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-11 | - | Extra Bolagsstämma 2020 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-16 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
| 2020-04-15 | - | Årsstämma |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oslo, 05 September 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 4,400 through the issuance of 44,000 new shares, each with a par value of NOK 0.10. The resolution is based on an authorisation to increase the share capital granted by the Company's general meeting on 21 April 2022.
The new shares are issued to employees of the Company in connection with the Company's employee incentive program. The new shares are issued at a subscription price of NOK 31.25.
Following registration of the share capital increase with the Norwegian Register of Business Enterprises, the Company will have a share capital of NOK 3,426,576.10, divided into 34,265,761 shares, each with a par value of NOK 0.10.
For further information, please contact:
Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632